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The emergence of bacterial strains that are resistant to virtually all currently available antibiotics underscores the importance
of developing new antimicrobial compounds. N-succinyl-l,l-diaminopimelic acid desuccinylase (DapE) is a metallohydrolase
involved in the meso-diaminopimelate (mDAP)/lysine biosynthetic pathway necessary for lysine biosynthesis and for building
the peptidoglycan cell wall. Because DapE is essential for Gram-negative and some Gram-positive bacteria, DapE has been
proposed as a good target for antibiotic development. Recently, l-captopril has been suggested as a lead compound for inhibition
of DapE, although its selectivity for this enzyme target in bacteria remains unclear (Gillner et al. (2009)). Here, we tested the
selectivity of l-captopril againstDapEin bacteria. SinceDapEknockoutstrainsofgram-negativebacteria areviableuponchemical
supplementation with mDAP, we reasoned that the antimicrobial activity of compounds targeting DapE should be abolished in
mDAP-containing media. Although l-captopril had modest antimicrobial activity in Escherichia coli and in Salmonella enterica,
to our surprise, inhibition of bacterial growth was independent both of mDAP supplementation and DapE over-expression. We
concludethat DapE is notthe maintarget of l-captopril inhibitioninthesebacteria. The methods implementedhere will be useful
for screening DapE-selective antimicrobial compounds directly in bacterial cultures.
1.Introduction
Most novel antibiotics that are developed are simply broad-
spectrum, structural variants of a limited set of known
bioactive compounds, many targeting the same enzymatic
pathways. Consequently, the risk that pathogenic bacterial
strains eventually evolve resistance against new antibiotics
is very high [1, 2]. To help combat the serious problem
of antibiotic resistance, it is imperative that new enzymatic
targets are identiﬁed and that their speciﬁc inhibitors
are developed. DapE, N-succinyl-l,l-diaminopimelic acid
desuccinylase of the meso-diaminopimelate (mDAP)/lysine
biosynthetic pathway of bacteria has been identiﬁed as
an attractive potential antibiotic target [3]. DapE is a
t e r m i n a le n z y m ef o rt h eh y d r o l y s i so ft h eN - s u c c i n y l - l,l-
diaminopimelic acid (SDAP) (Scheme 1) into succinate and
DAP [4]. Two of the products of this pathway (mDAP
and lysine) are essential components of the cell: lysine is a
protein-amino acid and DAP is a necessary component of
the peptidoglycan cell wall of all Gram-negative and many
Gram-positive bacteria [3, 5]. Since there is no enzyme in
mammals similar to DapE, the inhibitors of DapE could
potentially provide selective toxicity against bacteria and
have little or no eﬀect on humans.
DapE is a homodimeric enzyme, with each monomer
(41.6KDa) containing two structural domains: a dimeriza-
tion domain and a catalytic domain with a di-zinc active
site [4, 6]. Sequence alignment of all known DapE enzymes,
includingof E. coliand S. enterica, with the structurally char-
acterized DapE of H. inﬂuenzae and Neisseria meningitides,
points toward the very strict conservation of all the amino
acids that function as metal ligands and putative substrate
binding sites [4, 7–9].
Strong inhibition of metalloenzymes has often been
achieved by direct coordination of catalytic metals within



















Scheme 1: Structures of l-captopril and N-succinyl-l,l-diaminop-
imelic acid.
successfully in clinical drugs are the sulphonamides (as
carbonic anhydrase inhibitors) [10], suberoylanilide hydrox-
amic acid (SAHA) as histone deacetylase inhibitor [11],
andl-captopril(Scheme 1),which was theﬁrst marketed an-
tihypertension drug, targeting angiotensin I converting en-
zyme (ACE) [12]. Captopril binds to the catalytic zinc of
ACE through coordination by a sulfhydryl group. Although
captopril also shows some inhibitory activity towards other
zinc metalloproteases, this is typically several orders of
magnitude weaker than with ACE [12].
Recently, Gillner and colleagues [3] also identiﬁed cap-
topril amongst the best inhibitors of H. inﬂuenzae DapE in
a screen biased toward compounds containing zinc-binding
groups (including thiols, carboxylic acids, boronic acids,
phosphonates, and hydroxamates). Captopril was found to
bea low-micromolar inhibitorofDapE (IC50 = 3.3µM,Ki =
1.8µM) and had antimicrobial activity in bacteria (against
E. coli). However, here we present evidence that DapE is




Escherichia coli XL1-Blue was purchased from Stratagene.
Salmonella enterica serovar Typhimurium DapE knockout-
strain (TN5911) and the plasmid, pCM655/DapE, were
kindly provided by Prof. Miller [13]. E-medium [14] sup-
plemented with 0.4% glucose and a 0.4mM concentration
of the appropriate amino acids (Bachem) was used as a
minimal medium, and LB-medium was used as a rich
medium. As a supplement, meso-diaminopimelate (mDAP)
was added at 1mM (Bachem). l-captopril was purchased
from Sigma Aldrich. Sodium ampicillin, tetracycline and
chloramphenicol were used at ﬁnal concentrations of 60,
5, and 34µg/mL, respectively, when added to either liquid
or solid medium. Liquid cultures were aerated by shaking
on a rotary shaker (250rpm), and all growth incubations
were at 37◦C for 19 hours. Electro competent cells of S.
entericaandchemicalcompetentcellsofE.coliwereprepared
by standard protocols. IPTG and mDAP were used at a
ﬁnal concentration of 1mM. Agar (used at 1.5%) and
agarose (used at 1%), purchased from Invitrogen. T4-DNA
ligase and HindIII from New England Biolabs. All other
chemicals were purchased from Applichem,unless otherwise
speciﬁed.
3.Methods
An empty plasmid, pCM699, was derived from the plas-
mid, pCM655/DapE [13], by deleting the DapE gene by
HindIII digestion and religation of the vector backbone
(Table 1). The strain TN5911 (chloramphenicol resistance)
is a knockout strain for DapE and for several dipepti-
dases; therefore, mDAP has to be supplemented in both
minimal and enriched media. An appropriate source of
leucine and proline is also required in minimal medium
and supplementation with lysine provides better growth
(Prof. Miller; personal communication). Two strains were
derived from the knockout-strain TN5911 by transforming
the plasmids pCM655/dapE and pCM699 (strains TN5935
and TN5959, resp.). The plasmids (pCM655/dapE and
pCM699) were transformed into TN5911 by electroporation
(1.8kV, 0.1cm cuvettes) and recovered with 1mL of SOC
medium containing mDAP and chloramphenicol for 1 hour
at 37◦C in a shaking incubator and selected for plasmid
encoded ampicillin resistance. A single colony of each strain
TN5935 and TN5959 was picked and cultured in 5mL of
LB containing appropriate amounts of chloramphenicol,
ampicillin, and mDAP over night at 37◦Ci nas h a k i n g
incubator. The cultures of the two strains were diluted by
10 times (to dilute-out any remaining mDAP) and each
strain was plated in a minimal medium supplemented
or not with mDAP. In a similar manner, E. coli strains,
TN5960and TN5962,were derivedfromwild-typeXL1-Blue
by transforming the plasmid pCM699 and pCM655/DapE,
respectively. Analysis of soluble cell extracts of TN5960 and
TN5962by SDS-PAGE revealedthe presence ofan additional
species of about 42KDa in cells harbouring pCM655/DapE
(i.e., strain TN5962), corresponding to the expected size of
the recombinant S. enterica DapE in E. coli.
To test l-captopril inhibition, appropriate dilutions of
each strain (e.g., TN5935 and TN5959) were spread on
selection plates with and without mDAP. After spreading the
cultures, sterile paper discs soaked in several concentrations
of l-captoprilwereplacedoneachplate;alternatively,agiven
amount of compound was placed in powder form directly
at a deﬁned site on the agar, such that it could be covered
by a paper disk, and subsequently 10µL of sterile water
were added carefully on the disk. These selection plates were
incubated overnight at 37◦C.
4.Results
First, we compared the growth of E. coli in the presence
of l-captopril, with and without mDAP supplementation in
the agar-medium, using a disk-diﬀusion assay (Figure 1 and
Table 2). We conﬁrmed the modest inhibitory activity of l-
captopril in E. coli, as previously reported. However, to our
surprise, l-captopril antimicrobial activity was independentBioinorganic Chemistry and Applications 3
Table 1: Summary of strains and plasmids used in this work.
Plasmids Genotype Remarks
pCM655/DapE Plasmid with dapE gene Allows overexpression of DapE, thus rescuing DapE knockout strains (even in
absence of mDAP supplementation).Also confers ampicillin-resistance
pCM699 Plasmid without dapE gene Confers ampicillin-resistance, but does not genetically rescue DapE knockout
strains
S. enterica strains
TN5911 dapE knockout strain Strain does not grow in absence of mDAP supplementation
TN5935 TN5911 + pCM655/DapE DapE is overexpressed from plasmid and strain can grow in absence of mDAP
supplementation
TN5959 TN5911 + pCM699 Plasmiddoes not contain DapE and knockoutstrain does not grow in absence of
mDAP supplementation
E. coli strains
XL1-Blue Wildtype (from Stratagene) Has endogenous DapE and can grow in absence of mDAP supplementation
TN5960 XL1-Blue + pCM699 Plasmiddoes not contain DapE, but strain can grow in absence of mDAP
supplementation due to endogenous DapE
TN5962 XL1-Blue + pCM655/DapE In addition to endogenous DapE, this strain has plasmid-encoded DapE
overexpression (from S. enterica).
Table 2: Inhibition of E. coli growth by l-captopril.
Strain with endogenous DapE TN5960 (Plasmidwithout dapE gene) TN5962 (Plasmidwith dapE gene)
Supplemented with mDAP Yes No Yes No
Radius of zone of inhibition by l-captopril
25mg/mL 0.2cm 0.2cm 0.2cm 0.2cm
50mg/mL 0.2cm 0.2cm 0.2cm 0.2cm
20mg 1.2cm 1.2cm 1.2cm 1.2cm
of mDAP supplementation in E. coli. Moreover, the extent of
inhibition was also unaﬀected by heterologous expression of
DapE (from Salmonella enterica)i nE. coli (Figures 1(c) and
1(d)).
Second, considering that overexpression of DapE from S.
enterica in E. coli did not aﬀect l-captopril inhibition, we
set out to conﬁrm that the DapE plasmid was functional
for DapE expression. As previously reported [13], the DapE
knock-out strain (TN5911) of S. enterica only grows when
harbouring theplasmid carrying dapE gene(pCM655/DapE,
within strain TN5935) or by supplementing the medium
with mDAP, which is derived from the native product
of DapE hydrolytic activity, l,l-DAP. Consequently, strain
TN5935 (which harbours a plasmid-encoded dapE gene)
grew even in the absence of mDAP supplementation, since
it can produce its own DAP for cell-wall synthesis. As
negative control, we corroborated that the knockout strain
harbouring the corresponding “empty plasmid” (conferring
ampicillin resistance but with no dapE gene; strain TN5959)
did not grow in absence of mDAP supplementation.
Third, we tested the growth inhibiting-activity of l-
captopril in these various recombinant strains of S. enterica.
We hypothesised that if l-captopril was inhibiting DapE in
bacteria, then mDAP supplementation or DapE overexpres-
sion would alleviate the antimicrobial eﬀects of the drug.
Surprisingly, l-captopril inhibited the growth of TN5959
(harbouring an empty plasmid) despite the addition of
mDAP (Figure 2 and Table 3). We also tested whether the
modest l-captopril inhibition could be overcome by DapE
overexpression. Herealso,weweresurprised toﬁndthat sim-
ilar l-captopril inhibition of strain TN5935 (overexpressing
DapE), even when mDAP was additionally supplemented in
the medium.
The zone of inhibition was slightly more in strain
TN5935 compared to TN5959, although this diﬀerence was
very subtle and couldonly be seen when the paper diskswere
soaked at the concentrations 25mg/mL and 50mg/mL, but
not when 20mg were added (Table 3); at the latter amount
of compound, the extent of inhibition was signiﬁcant and
identical to that observed in TN5959. We speculate that
this marginally higher l-captopril inhibition in the strain
overexpressing DapE (TN5935) compared with TN5959
is due to the high metabolic load of the cell caused by
overexpression of DapE.
Taken together, these data strongly suggest that l-
captopril modestly inhibits both S. enterica and E. coli to a
similar extent, but in a DapE-independent manner.
5.Discussion
Diaminopimelic acid is an essential precursor for cell wall
synthesis in many bacteria, including E. coli and S. enterica
[5, 15]. Inhibition of DapE from H. inﬂuenzae in vitro




















































































































(d) TN5962, no mDAP
Figure 1: DapE independent inhibition of E. coli by l-captopril. (a) The strain has constitutively expressed endogenous dapE gene, and the
medium was also supplemented with mDAP; (b) the strain has constitutively expressed endogenous dapE gene but the medium was not
supplemented with mDAP; (c) the strain has overexpressed plasmid encoded DapE (in addition to the constitutively expressed endogenous
DapE) and the medium was also supplemented with mDAP; (d) the strain has overexpressed plasmid encoded DapE (in addition to the
constitutively expressed endogenous DapE) but the medium was not supplemented with mDAP.
Table 3: Inhibiton of Salmonella enterica growth by l-captopril.
DapE-knockout strains TN5935 (Plasmidwith dapE gene) TN5959 (Plasmidwithout dapE gene)
Supplemented with mDAP Yes No Yes No
Radius of zone of inhibition by l-captopril
25mg/mL 0.1cm 0.1cm 0.0cm No growth
50mg/mL 0.5cm 0.5cm 0.1cm No growth
20mg 1.7cm 1.7cm 1.7cm No growth
was recently reported [3]. In the process of enzymatically
characterizing mutant variants of Salmonella enterica DapE,
we decided to test the inhibition of DapE with l-captopril in
bacteria. We hypothesised that if l-captopril was inhibiting
bacterial growth by inhibiting DapE, then mDAP supple-
mentation in the growth media would overcome drug-
i n h i b i t i o n .H o w e v e r ,t oo u rs u r p r i s ew ef o u n dt h a tl-
captopril inhibits the bacterial strains (S. enterica and E. coli)
in a DapE-independent manner.
The putative substrate binding site and the metal coordi-
nating residues are very much conserved in the DapE of E.
coli, S. enterica,a n dH. inﬂuenzae, all of which are thought to
have similar binuclear metal-centres and identical catalytic
mechanism [4, 7–9]. Consequently, considering such struc-
tural and functional conservation among DapE from these
various bacteria, it would be expected that l-captopril is
able to inhibit the diﬀerent homologs in a similar manner,
proving potentially active as a broad-selectivity antibiotic.
It is noteworthy that diﬀerent isoforms of DapE (e.g.,
from diﬀerent organisms or with diﬀerent metal contents)
could be inhibited diﬀerently, thereby making it diﬃcult
to ﬁnd a single broad-spectrum antibiotic targeting DapE.
Our data show that l-captopril is not a broad-spectrum
antibiotic targeting DapE in bacteria, because it neither
targets DapE in E. coli nor in S. enterica.S i n c et h ee x t e n t
of inhibition by l-captopril in bacteria was similar in all of
our experiments in E. coli and S. enterica and independent
of DapE, we suggest that the modest antimicrobial activity
of this compound is probably due to inhibition of hitherto-
unidentiﬁed metalloproteins other than DapE.
In summary, our results show that despite the reported










































































































(d) TN5959, no mDAP
Figure 2: DapE independent inhibition of Salmonella enterica by l-captopril. (a) The knockout-strainhas plasmid encoded dapE gene, and
the medium is also supplemented with mDAP; (b) the knockout-strainhas plasmid encoding dapE gene but no mDAP supplemented in the
medium; (c) the knockout-strain has no plasmid encoding dapE gene but the medium was supplemented with mDAP; (d) the knockout-
strain has no plasmid encoding dapE gene and no mDAP was supplemented.
in vitro, it is very unlikely that DapE inhibition con-
tributes to any signiﬁcant antimicrobial activity in Gram-
negative bacterialcultures.Therefore,l-captoprilisamodest
antibiotic, inhibiting Gram-negative bacteria at high doses,
but its mechanism of action or molecular target remains
unknown.
Finally, considering that DapE is a promising antibiotic
target, the failure of a lead-compound that inhibits DapE
in vitro to show any measurable anti-DapE eﬀect in bacteria
provides a sobering reminder of the diﬃculty of translating
in vitro data to eﬀects in vivo, even in pure microbiological
cultures. However, despite our ﬁnding that captopril does
not lead to DapE inhibition in bacteria, the development of
other (more eﬀective) DapE inhibitors in vitro and in vivo
continues to be a very worthy goal and a promising line
of research toward new antibiotics. We suggest that mDAP
supplementation, as described here, will oﬀer a facile and
very robust method for conﬁrming the selectivity of novel
antibiotics targeting DapE in bacteria.
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